This is the third in a series of seven articles discussing the Recall Root Cause Research
project conducted by the Division of Manufacturing and Product Quality, Center for Drug …

A real-time polymerase chain reaction (RT-PCR) assay was developed to detect
Burkholderia cepacia in pharmaceutical products contaminated with low levels of bacteria …

Burkholderia cepacia (formerly Pseudomonas cepacia) was once thought to be a single
bacterial species but has expanded to the Burkholderia cepacia complex (Bcc), comprising …

The Burkholderia cepacia complex (BCC) includes opportunistic pathogenic bacteria that
have occasionally been recovered from various pharmaceutical products, including …

In the past 2 decades, Burkholderia cepacia has emerged as a human pathogen causing
numerous outbreaks, particularly among cystic fibrosis (CF) patients. One highly …

Chlorhexidine gluconate (CHX) and benzalkonium chloride (BZK) formulations are
frequently used as antiseptics in healthcare and consumer products. Burkholderia cepacia …

In the 1990s several biocontrol agents on that contained Burkholderia strains were
registered by the United States Environmental Protection Agency (EPA). After risk …

The Burkholderia cepacia complex (Bcc) is a group of opportunistic pathogenic bacteria with
a remarkable metabolic capacity and broad genotypic/phenotypic plasticity, allowing their …

Burkholderia cepacia is a plant phytogen and is known as a hardy and versatile organism.
Over the past two decades it has emerged as a pathogen in the cystic fibrosis (CF) …

Background Burkholderia cepacia complex (Bcc) is well-known for intrinsic resistance to
certain antiseptics. We experienced a sudden rise in Bcc bloodstream infections in a 786 …